Adagene Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADAG Nasdaq 2836 www.adagene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adagene Inc.

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - Sep 10th, 2026 6:00 am
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates - Sep 9th, 2026 6:00 am
Adagene to Participate in Three Upcoming Investor Conferences - Aug 20th, 2026 6:00 am
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates - Aug 12th, 2026 5:30 am
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know - Jun 5th, 2026 10:00 am
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Jun 2nd, 2026 7:40 am
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer - May 19th, 2026 3:07 pm
Adagene to Participate in Two Upcoming Investor Conferences - May 12th, 2026 6:30 am
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer - Apr 20th, 2026 8:15 am
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types - Apr 17th, 2026 2:01 pm
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Apr 14th, 2026 5:00 am
Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed? - Apr 4th, 2026 11:09 pm
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Apr 2nd, 2026 5:10 am
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Apr 2nd, 2026 5:01 am
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response - Apr 2nd, 2026 5:00 am
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - Apr 1st, 2026 3:00 pm
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Mar 17th, 2026 2:35 pm
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon - Mar 9th, 2026 6:48 pm
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk - Feb 25th, 2026 3:25 pm